Anemia News and Research RSS Feed - Anemia News and Research

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Eliglustat drug improves liver, spleen size and hemoglobin level in adults with Gaucher disease type 1

Among previously untreated adults with Gaucher disease type 1, a genetic disease in which there is improper metabolism due to a defect in an enzyme, treatment with the drug eliglustat resulted in significant improvements in liver and spleen size hemoglobin level, and platelet count, according to a study in the February 17 issue of JAMA. [More]
DaVita HealthCare Partners announces financial results for fourth quarter 2014

DaVita HealthCare Partners announces financial results for fourth quarter 2014

DaVita HealthCare Partners Inc. today announced results for the quarter and year ended December 31, 2014. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the quarter and year ended December 31, 2014 was $208 million and $723 million, or $0.96 and $3.33 per share, respectively. [More]
Longer donor leukocyte telomere length linked to improved survival following HCT

Longer donor leukocyte telomere length linked to improved survival following HCT

Among patients with severe aplastic anemia who received stem cell transplant from an unrelated donor, longer leukocyte (white blood cells) telomere length (a structure at the end of a chromosome) was associated with increased overall survival at 5 years, according to a study in the February 10 issue of JAMA. [More]
Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Study shows low-dose oral iron supplementation after blood donation reduces hemoglobin recovery time

Among blood donors with normal hemoglobin levels, low-dose oral iron supplementation, compared with no supplementation, reduced the time to recovery of the postdonation decrease in hemoglobin concentration in donors with low or higher levels of a marker of overall iron storage (ferritin), according to a study in the February 10 issue of JAMA. [More]
Readmissions after surgery associated with new postdischarge complications, shows study

Readmissions after surgery associated with new postdischarge complications, shows study

In a study that included readmission information from nearly 350 hospitals, readmissions the first 30 days after surgery were associated with new postdischarge complications related to the surgical procedure and not a worsening of any medical conditions the patient already had while hospitalized for surgery, according to a study in the February 3 issue of JAMA. [More]
FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

FDA accepts Sangamo BioSciences' IND for SB-BCLmR-HSPC genome editing approach

Sangamo BioSciences, Inc. announced today that an Investigational New Drug (IND) application for the company's SB-BCLmR-HSPC genome editing approach, which is designed to provide a one-time lasting therapy for beta-thalassemia, has been accepted by the U.S. Food and Drug Administration and is now active. [More]
Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints. [More]
Study examines why hydroxyurea yields mixed results in children with sickle cell disease

Study examines why hydroxyurea yields mixed results in children with sickle cell disease

Electronic medication monitoring caps may help physicians put together the puzzle of why children taking a medicine that promises to curb sickle cell disease are showing mixed, confusing results. [More]
Some genetic features associated with modern diseases are ancient

Some genetic features associated with modern diseases are ancient

Psoriasis, a chronic skin condition, can cause rashes that itch and sting. So why would a genetic susceptibility to this and other ailments persist for hundreds of thousands of years, afflicting our ancient ancestors, and us? [More]
SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients. [More]
Loyola University Medical Center earns Baby-Friendly designation

Loyola University Medical Center earns Baby-Friendly designation

Loyola University Medical Center has earned the coveted Baby-Friendly designation. This verifies that the hospital has implemented the ten steps to help new mothers successfully breastfeed. [More]
Researchers reveal key factor in understanding elevated cancer risk linked to gene therapy

Researchers reveal key factor in understanding elevated cancer risk linked to gene therapy

National Institutes of Health researchers have uncovered a key factor in understanding the elevated cancer risk associated with gene therapy. They conducted research on mice with a rare disease similar to one in humans, hoping their findings may eventually help improve gene therapy for humans. Researchers at the National Human Genome Research Institute, part of NIH, published their research in the Jan. 20, 2015, online issue of the Journal of Clinical Investigation. [More]
Researchers find genetic mutation that causes glycogen storage disease type IIIa in Inuit

Researchers find genetic mutation that causes glycogen storage disease type IIIa in Inuit

A team of Canadian and Japanese researchers has identified the genetic mutation responsible for glycogen storage disease type IIIa in Inuit in northern Quebec, Canada, in a study published in CMAJ (Canadian Medical Association Journal). [More]
John H. Postlethwait selected to receive GSA's George W. Beadle Award

John H. Postlethwait selected to receive GSA's George W. Beadle Award

The Genetics Society of America is pleased to announce that John H. Postlethwait, PhD (University of Oregon) has been selected to receive the Society's George W. Beadle Award for outstanding contributions to the community of genetics researchers. [More]
EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm point of care (POC) hemoglobin analyzer at Arab Health 2015, 26-29th January, Dubai, UAE. Also on Stand Z1G30, EKF will be discussing its new liquid-stable assay* for early sepsis detection, as well as previewing SensPoint, a new hand-held lactate analyzer with built-in connectivity functions to hospital or laboratory information systems. [More]
People with iron overload disease are more vulnerable to Vibrio vulnificus infections

People with iron overload disease are more vulnerable to Vibrio vulnificus infections

Every summer, the news reports on a bacterium called Vibrio vulnificus found in warm saltwater that causes people to get sick, or die, after they eat raw tainted shellfish or when an open wound comes in contact with seawater. [More]
3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea. [More]
Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). [More]
CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients. [More]
Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia. [More]
Advertisement
Advertisement